Open-Label, Long-Term (> 1 Year) Extension Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
Open-Label, Long-Term (> 1 Year) Extension Study of Pitavastatin in Elderly Patients With Primary Hypercholesterolemia or Combined Dyslipidemia
This is an open-label extension study of NK-104-306 (NCT00257686) for elderly patients with hypercholesterolemia or combined dyslipidemia.
This was an open-label study of 60 weeks duration in elderly patients (≥65 years) with primary hypercholesterolemia or combined dyslipidemia who completed the 12 week treatment in study NK-104-306 and who met the inclusion/exclusion criteria. Patients who qualified started open-label treatment with pitavastatin 2 mg QD. The dose of pitavastatin could be increased to 4 mg QD after at least 8 weeks of treatment at 2 mg QD, in patients who failed to attain their LDL-C target.
Inclusion Criteria:
Exclusion Criteria:
Bad Soden/Taunus, Germany
Melcherstaette, Germany
Offenbach/M, Germany
Beersheva, Israel
Jerusalem Ein Kerem, Israel
Mount Scopus Jerusalem, Israel
Cornwall, United Kingdom
Wiltshire, United Kingdom
Wiltshire, United Kingdom
Wiltshire, United Kingdom
Yorkshire, United Kingdom